A Quantitative Analysis of Adverse Events and “Overwarning” in Drug Labeling
Archives of Internal MedicinePublished 23 May 2011Open access
Jon Duke
Citations45
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
This project was funded by grants from Region Skåne, the Swedish National Insurance Agency, Hässleholm Hospital, the Swedes Research Council, and the Faculty of Medicine, Lund University.
Abstract
or work rules may influence incidence of CTS.Intercountry differences in incidence could also reflect differences in CTS-associated disorders such as diabetes and inflammatory joint diseases.
Keywords
MedicineEconomics, Econometrics and FinancePharmacology, Toxicology and Pharmaceutics
JAMADrug Labeling Revisions—Guaranteed to Fail?
45 Citations2000Raymond L. Woosley
It was found that patients with contraindications for the use of cisapride continued to receive the drug at nearly the same rate after the warnings were issued as before they were issued, and the pharmaceutical manufacturer left the drug from general use and restrict its availability.
PubMedRequirements on content and format of labeling for human prescription drug and biological products. Final rule.
41 Citations2006
The final rule revises current regulations to require that the labeling of new and recently approved products include highlights of prescribing information and a table of contents, which will make it easier for health care practitioners to access, read, and use information in prescription drug labeling.
PubMedADESSA: A Real-Time Decision Support Service for Delivery of Semantically Coded Adverse Drug Event Data.
36 Citations2010Jon Duke, Jeff Friedlin
A natural language processing application which extracts adverse events from Structured Product Labels and generates a standardized ADE knowledge base and a decision support service that consumes a Continuity of Care Document and returns a list of patient-specific ADE's.
New England Journal of MedicineHighlights and a Hidden Hazard — The FDA's New Labeling Regulations
25 Citations2006Jerry Avorn, William H. Shrank
The FDA is trying to make the official descriptions of prescription drugs more helpful, but the most troubling aspect of the FDA's new plan has nothing to do with providing information to prescribers.
Journal of the American Medical Informatics AssociationStructured Product Labeling Improves Detection of Drug-intolerance Issues
14 Citations2008Gunther Schadow
The SPL-based approach is more sensitive and suggests that mapping local dictionaries to SPL, and enhancing the depth and breadth of coverage of SPL content are worth accelerating.